On February 13, 2026, Ampersand Capital Partners completed the acquisition of Purna Pharmaceuticals, a Belgium-based CDMO specializing in liquid and semi-solid dosage forms.
Strategic Objectives
This acquisition serves as a cornerstone for Ampersand’s strategy to create a powerful trans-Atlantic alliance between Purna and MedPharm. This partnership aims to become a premier provider across Europe and North America for:
-
Pharmaceutical drug development and formulation.
-
Manufacturing of topical and transdermal medications.
Key Entities Involved
-
Purna Pharmaceuticals: Operating since 1986, the company offers GXP-compliant contract services for a diverse client base, ranging from biotech startups to multinational pharmaceutical giants.
-
Ampersand Capital Partners: A healthcare-focused investment firm with approximately $3 billion in assets under management.
-
Achelous Partners: Served as the exclusive investment banking and financial adviser to Purna for this transaction.
Leadership from both organizations emphasized that the move would bolster innovation, expand production capacity, and leverage Ampersand’s extensive life sciences network while maintaining Purna’s customer-centric culture.